

DAFTAR PUSTAKA

1. WHO. Infection prevention and control recommendations [Internet]. U.S. National Library of Medicine; 2014 [cited 2021 Aug 3]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK214350/>
2. Quinton LJ, Walkey AJ, Mizgerd JP. Integrative physiology of pneumonia. *Physiol Rev.* 2018;98(3):1417–64.
3. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis.* 2016;63(5):e61–111.
4. Pangesti KN. Surveilans SARI (Severe Acute Respiratory Infection) di Indonesia. Jakarta Pusat; 2011.
5. Hackstein H, Kranz S, Lippitsch A, Wachtendorf A, Kershaw O, Gruber AD, et al. Modulation of respiratory dendritic cells during *Klebsiella pneumoniae* infection. *Respir Res.* 2013;14(1):1–11.
6. Cao F, Wang X, Wang L, Li Z, Che J, Wang L, et al. Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance *Klebsiella pneumoniae* in mice. *Biomed Res Int.* 2015;2015.
7. Outcome C, Tirtonegoro S. Prevalensi Multidrug-Resistant *Klebsiella pneumoniae* dan Evaluasi Kesesuaian Antibiotik Empiris Berdasarkan Nilai Prediksi Farmakokinetik Terhadap Outcome Klinis di RSUP Dr . Soeradji Tirtonegoro Klaten Prevalence of Multi Drug-Resistent *Klebsiella pneumoni*. 2020;16(1):27–33.
8. Kemenkes RI. Laporan Nasional Riset Kesehatan Dasar. Kementerian Kesehat RI. 2018;1–582.
9. Rai IBN, Artana IG. B. “Workshop On Pneumonia” Deal The Challenge - Improve The Outcome. *Work Pneumonia Deal Chall - Improv Outcome.* 2016;53(9):1–272.

10. Widyastuti P.N. Evaluasi Penggunaan Antibiotik Pada Pasien Pediatri Dengan Pneumonia Menggunakan Metode Gyssens Di Rsud Kota Yogyakarta Periode 2017. 2019;8(5):55.
11. Su M, Jia Y, Li Y, Zhou D, Jia J. Probiotics for the Prevention of Ventilator-Associated Pneumonia: A Meta-Analysis of Randomized Controlled Trials. *Respir Care*. 2020 May;65(5):673-685. doi: 10.4187/respcare.07097. Epub 2020 Mar 3. PMID: 32127415.
12. Petrof EO, Dhaliwal R, Manzanares W, Johnstone J, Cook D, Heyland DK. Probiotics in the critically ill: a systematic review of the randomized trial evidence. *Crit Care Med*. 2012 Dec;40(12):3290-302. doi: 10.1097/CCM.0b013e318260cc33. PMID: 22975886.
13. Johnstone J, Meade M, Lauzier F, et al. Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial. *JAMA*. 2021;326(11):1024-1033. doi:10.1001/jama.2021.13355
14. Khailova L, Baird CH, Rush AA, McNamee EN, Wischmeyer PE. Lacticaseibacillus rhamnosus GG improves outcome in experimental pseudomonas aeruginosa pneumonia: potential role of regulatory T cells. *Shock*. 2013 Dec;40(6):496-503. doi: 10.1097/SHK.0000000000000066. PMID: 24240593; PMCID: PMC5592098.
15. Khailova L, Baird CH, Rush AA, Barnes C, Wischmeyer PE. Lacticaseibacillus rhamnosus GG treatment improves intestinal permeability and modulates inflammatory response and homeostasis of spleen and colon in experimental model of Pseudomonas aeruginosa pneumonia. *Clin Nutr*. 2017 Dec;36(6):1549-1557. doi: 10.1016/j.clnu.2016.09.025. Epub 2016 Oct 1. PMID: 27745813; PMCID: PMC5641477.
16. Manzoor A, Begum A, Munir S, Zahra R, Iqbal Z, Akhtar MS, et al. Efficacy of locally isolated lactic acid bacteria against antibiotic-resistant

- uropathogens. *Jundishapur J Microbiol.* 2016;9(1):e18952. doi: 10.5812/JJM.18952.
17. Savinova OS, Glazunova OA, Moiseenko KV, Begunova AV, Rozhkova IV, Fedorova TV. Exoproteome analysis of antagonistic interactions between the probiotic bacteria *LimosiLacticaseibacillus reuteri* LR1 and *Lacticaseibacillus rhamnosus* F and multidrug resistant strain of *Klebsiella pneumoniae*. *Int J Mol Sci.* 2021;22(20):10995. doi: 10.3390/ijms222010999.
 18. Fangous MS, Alexandre Y, Hymery N, Gouriou S, Arzur D, Blay GL, Berre RL. Lactobacilli intra-tracheal administration protects from *Pseudomonas aeruginosa* pulmonary infection in mice - a proof of concept. *Benef Microbes.* 2019 Dec 9;10(8):893-900. doi: 10.3920/BM2019.0069. Epub 2019 Oct 10. PMID: 31965833.
 19. Remington LT, Sligl WI. Community-acquired pneumonia. *Curr Opin Pulm Med.* 2014;20(3):215–24.
 20. Integrated Taxonomic Information System. Integrated Taxonomic Information System - Report: *Klebsiella pneumoniae*. [Internet]. 2012. Available from: https://www.itis.gov/servlet/SingleRpt/SingleRpt?search_topic=TSN&search_value=9751#null [Accessed 2022 Apr 1].
 21. Wang G, Zhao G, Chao X, Xie L, Wang H. The Characteristic of Virulence, Biofilm and Antibiotic Resistance of *Klebsiella pneumoniae*. *Int J Environ Res Public Health.* 2020 Aug 28;17(17):6278. doi: 10.3390/ijerph17176278. PMID: 32872324; PMCID: PMC7503635.
 22. Podschun R, Ullmann U. *Klebsiella* spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clin Microbiol Rev.* 1998 Oct;11(4):589-603. doi: 10.1128/CMR.11.4.589. PMID: 9767057; PMCID: PMC88898.
 23. Shahab Qureshi M. *Klebsiella* Infections Treatment & Management [Internet]. Medscape; 2023 [cited 2023 Aug 10]. Available from: <https://emedicine.medscape.com/article/219907-treatment>.

24. van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β -Lactam/ β -Lactamase Inhibitor Combinations. *Clin Infect Dis*. 2016 Jul 15. 63 (2):234-41.
25. Loutit JS, et al. Meropenem-Vaborbactam (MV) Compared With Piperacillin-Tazobactam (PT) in the Treatment of Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP) in a Phase 3 Randomized, Double-Blind, Double-Dummy Trial (TANGO 1). *Open Forum Infectious Diseases*. 2016. Vol. 3. No. suppl_1:Presented at the Infectious Diseases Society of America IDWeek. San Diego, CA. October 4-8, 2017.
26. Pranita D Tamma. IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram Negative Infections: Version 1.0. March 7 2022.
27. Doyle D, Peirano G, Lascols C, Lloyd T, Church DL, Pitout JD. Laboratory detection of Enterobacteriaceae that produce carbapenemases. *J Clin Microbiol*. 2012 Dec. 50(12):3877-80.
28. Ashurst JV, Dawson A. *Klebsiella pneumoniae*. [Updated 2023 Jan 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK519004/>
29. FAO/WHO. Food and Agriculture Organization and World Health Organization Expert Consultation. Evaluation of Health and Nutritional Properties of Powder Milk and Live Lactic Acid Bacteria. 2001. Córdoba, Argentina: Food and Agriculture Organization of the United Nations and World Health Organization.
30. K Gogineni V, Morrow LE. Probiotics: Mechanisms of action and clinical applications. *Journal of Probiotics & Health* 2013;01. doi:10.4172/2329-8901.1000101.
31. Fijan S. Microorganisms with claimed probiotic properties: An overview of recent literature. *International Journal of Environmental Research and Public Health* 2014;11:4745–67. doi:10.3390/ijerph110504745.

32. Fuller R. History and development of Probiotics. *Probiotics* 1992:1–8. doi:10.1007/978-94-011-2364-8_1.
33. Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. *Am J Clin Nutr*. 1999;69(5):1052S-1057S.
34. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. *BMJ*. 2018;361:k2179.
35. Toma MM, Pokrotnieks J. Probiotics as functional food: microbiological and medical aspects. *Acta Univ Latviensis*. 2006;710:117-129.
36. Hao WL, Lee YK. Microflora of the gastrointestinal tract. *Public Health Microbiol*. 2004;491-502.
37. Wen L, Duffy A. Factors influencing the gut microbiota, inflammation, and type 2 diabetes. *J Nutr*. 2017;147(7):1468S-1475S.
38. Raheem A, Liang L, Zhang G, Cui S. Modulatory effects of probiotics during pathogenic infections with emphasis on immune regulation. *Front Immunol*. 2021;12:616713.
39. Cruz CS, Ricci MF, Vieira AT. Gut microbiota modulation as a potential target for the treatment of lung infections. *Front Pharmacol*. 2021;12:2352.
40. Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A. Probiotic mechanisms of action. *Ann Nutr Metab*. 2012;61(2):160-174.
41. Vieira AT, Teixeira MM, Martins FS. The role of probiotics and prebiotics in inducing gut immunity. *Front Immunol*. 2013;4:445.
42. Harzallah D, Belhadj H. Lactic acid bacteria as probiotics: characteristics, selection criteria and role in immunomodulation of human GI mucosal barrier. In: Kongo M, editor. *Lactic Acid Bacteria—R & D for Food, Health and Livestock Purposes*. 2013. p. 197-216.
43. Doron S, Snyderman DR. Risk and safety of probiotics. *Clin Infect Dis*. 2015;60(Suppl 2):S129-S134.

44. Salminen, Seppo, et al. "The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics." *Nature Reviews Gastroenterology & Hepatology*. 2021; 649-667.
45. Sencio, Valentin, et al. "Gut dysbiosis during influenza contributes to pulmonary pneumococcal superinfection through altered short-chain fatty acid production." *Cell reports*. 2020; 2934-2947.
46. Antunes, Krist Helen, et al. "Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon response." *Nature communications*. 2019; 1-17.
47. Forestier, Christiane, et al. "Oral probiotic and prevention of *Pseudomonas aeruginosa* infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients." *Critical care*. 2008; 1-10.
48. Morrow, Lee E., Marin H. Kollef, and Thomas B. Casale. "Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial." *American journal of respiratory and critical care medicine*. 2010; 1058-1064.
49. Shimizu, Kentaro, et al. "Synbiotics modulate gut microbiota and reduce enteritis and ventilator-associated pneumonia in patients with sepsis: a randomized controlled trial." *Critical care*. 2018; 1-9.
50. Westerik N, Kort R, Sybesma W, Reid G. *Lacticaseibacillus rhamnosus* probiotic food as a tool of empowerment across the value chain in africa. 2018; 9(1501).
51. Yan F, Polk DB. *Lacticaseibacillus rhamnosus* GG: an updated strategy to use microbial products to promote health. National Institutes of Health. 2012; 4(2): 77-84.
52. Integrated Taxonomic Information System, 2012. Integrated Taxonomic Information System - Report: *Lacticaseibacillus rhamnosus*. [Online]. Available _____ at:

https://www.itis.gov/servlet/SingleRpt/SingleRpt?search_topic=TSN&search_value=962649#null [Accessed 1 April 2022].

53. Gorbach, S., Doron, S. and Magro, F. 'Lacticaseibacillus rhamnosus GG', The Microbiota in Gastrointestinal Pathophysiology: Implications for Human Health, Prebiotics, Probiotics, and Dysbiosis. 2017. pp. 79–88. doi: 10.1016/B978-0-12-804024-9.00007-0.
54. Liu, Fang, et al. "Effects of phenyllactic acid as sanitizing agent for inactivation of *Listeria monocytogenes* biofilms." *Food Control*. 2017; 72-78.
55. Maruddin, Fatma, Farida Nur Yulianti, and Andi Nurul Mukhlisah. "Pengaruh Kombinasi Starter Kultur *Lacticaseibacillus plantarum* dan *Lacticaseibacillus acidophilus* terhadap Karakteristik Mikrobiologis dan Kimiawawi pada Minuman Fermentasi." *Jurnal Sains dan Teknologi Peternakan*. 2020; 36-41.
56. Hudson, J. A. "*Staphylococcus aureus*." *Encyclopedia of meat sciences*. 2014; 376e381.
57. Kurniati, Evi, Fajri Anugroho, and Akhmad Adi Sulianto. "Analisis pengaruh pH dan suhu pada desinfeksi air menggunakan microbubble dan karbondioksida bertekanan." *Jurnal Pengelolaan Sumberdaya Alam Dan Lingkungan (Journal of Natural Resources and Environmental Management)*. 2020; 247-256.
58. Wulandari S, Aryati F, Ramadhan AM, Rahmadani A. Sintesis Senyawa phenyllactic acid (2-hydroxy-3-phenylpropionic acid) Dan Aktivitasnya Sebagai antibakteri. *Jambura Journal of Chemistry*. 2021 Oct 17;3(2):91–8. doi:10.34312/jambchem.v3i2.11197
59. Ning, Yawei, et al. "Antibacterial activity of phenyllactic acid against *Listeria monocytogenes* and *Escherichia coli* by dual mechanisms." *Food Chemistry*. 2017; 533-540.
60. Lagrafeuille R, Lamas B, Blugeon S, El-Benna J, Bonnet R, Ardid D, et al. Opposing effect of *Lacticaseibacillus* on in vitro *Klebsiella*

- pneumoniae in biofilm and in an in vivo intestinal colonisation model. *Benef Microbes*. 2017;9(1):87-100.
61. Mandal SP, Halder D. Exploring anti-Klebsiella pneumoniae activity of probiotic lactobacilli of curd origin. *Acta Sci Microbiol*. 2018;1(4):49-53.
 62. Shehata HR, Newmaster SG. A validated real-time PCR method for the specific identification of probiotic strain *Lactocaseibacillus rhamnosus* GG (ATCC 53103). *J AOAC Int*. 2020 Nov;103(6):1604-1609. doi: 10.1093/jaoacint/qsaa063. PMID: 33247747.
 63. Harata G, Yoshinari K, Matsumoto M, Nagaoka K, Okuda S, Arai K. Intranasal administration of *Lactocaseibacillus rhamnosus* GG protects mice from H1N1 influenza virus infection by regulating respiratory immune responses. *Lett Appl Microbiol*. 2010;50(6):597-602.
 64. Fachri M, Hatta M, Massi MN, Santoso A, Wikanningtyas TA, Dwiyantri R, et al. The strong correlation between ADAM33 expression and airway inflammation in chronic obstructive pulmonary disease and candidate for biomarker and treatment of COPD. *Sci Rep*. 2021;11:23162. doi: 10.1038/s41598-021-02615-2.
 65. Syawal P, Budu B, Hatta M, Massi MN, Ichsan AM, Minhajat R. Comparison between the triamcinolone and bevacizumab subconjunctivals and changes in Interleukin-1 mRNA expression in pterygium. *J Taibah Univ Med Sci*. 2021. doi: 10.1016/j.jtumed.2021.07.009.
 66. Hatta M, Surachmanto EE, Islam AA, Wahid S. Expression of mRNA IL-17F and sIL-17F in atopic asthma patients. *BMC Res Notes*. 2017;10:202. doi: 10.1186/s13104-017-2517-9.
 67. Yamakawa I, Kojima H, Terashima T, Katagi M, Oi J, Urabe H, et al. Inactivation of TNF- α ameliorates diabetic neuropathy in mice. *Am J Physiol Endocrinol Metab*. 2011 Nov;301(5):E844-52. doi: 10.1152/ajpendo.00029.2011. Epub 2011 Aug 2. PMID: 21810933; PMCID: PMC3213998.

68. Joshi L, Ponnana M, Sivangala R, Chelluri LK, Nallari P, Penmetsa S, et al. Evaluation of TNF- α , IL-10 and IL-6 cytokine production and their correlation with genotype variants amongst tuberculosis patients and their household contacts. *PLoS One*. 2015 Sep 11;10(9):e0137727. doi: 10.1371/journal.pone.0137727. PMID: 26359865; PMCID: PMC4567353.
69. Rosamarlina R, Hatta M, Djaharuddin I, Patellongi ID, Susanto AD, Islam AA, et al. The changes of HIF-1 α and ICAM-1 expression after Miana (*Coleus scutellarioides* [L]) treatment in Balb/C mice with *Mycobacterium tuberculosis* infection. *Biomed Pharmacol J*. 2022;15(1):73-81. doi: 10.13005/bpj/2344.
70. Syawal P, Budu B, Hatta M, Massi MN, Ichsan AM, Minhajat R. Comparison between the triamcinolone and bevacizumab subconjunctivals and changes in Interleukin-1 mRNA expression in pterygium. *J Taibah Univ Med Sci*. 2021. doi: 10.1016/j.jtumed.2021.07.009.
71. Febriza A, Natzir R, Hatta M, Uiterwaal SP, As'ad S, Budu B, et al. Curcumin effects in inducing mRNA gene cathelicidin antimicrobial peptide (CAMP) in Balb/c mice infected with *Salmonella Typhi*. *J Biol Res*. 2020;93(2):76-80. doi: 10.4081/jbr.0.8942.
72. Amsyah UK, Hatta H, Tahir H, Alam G, Asmawati AI. Expression of IL-10 in *A.actinomycetemcomitans* induced rats treated by purple Miana leaves. *Biomed Pharmacol J*. 2019;12(4):2099-2104. doi: 10.13005/bpj/1845.
73. Sitepu RK, Natzir R, Warsinggih, Hatta M, Rudiman R, Labeda I, et al. Relation between expression of hMLH1 and p53 mRNA genes in the feces of patients with colorectal carcinoma: cross-sectional study. *Ann Med Surg*. 2022;76:103237. doi: 10.1016/j.amsu.2021.103237.
74. Sharma S, Mohan H, Sharma S, Chhibber S. A comparative study of induction of pneumonia in mice with planktonic and biofilm cells of

- Klebsiella pneumoniae. Microbiol Immunol. 2011 May;55(5):295-303. doi: 10.1111/j.1348-0421.2011.00317.x. PMID: 21272064.
75. Wu T, Xu F, Su C, Li H, Lv N, Liu Y, et al. Alterations in the gut microbiome and cecal metabolome during Klebsiella pneumoniae-induced pneumosepsis. Front Immunol. 2020 Jul 31;11:1331. doi: 10.3389/fimmu.2020.01331. PMID: 32849494; PMCID: PMC7411141.
76. Balouiri M, Sadiki M, Ibsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. J Pharm Anal. 2016 Apr;6(2):71-79. doi: 10.1016/j.jpha.2015.11.005. Epub 2015 Dec 2. PMID: 29403965; PMCID: PMC5762448.
77. Shokryazdan P, Sieo CC, Kalavathy R, Liang JB, Alitheen NB, Faseleh Jahromi M, Ho YW. Probiotic potential of Lacticaseibacillus strains with antimicrobial activity against some human pathogenic strains. Biomed Res Int. 2014;2014:927268. doi: 10.1155/2014/927268. Epub 2014 Jul 3. PMID: 25105147; PMCID: PMC4106073.
78. Kesavelu D, Jog P. Current understanding of antibiotic-associated dysbiosis and approaches for its management. Therapeutic Advances in Infectious Disease. 2023 Jan;10:204993612311544. doi:10.1177/20499361231154443

LAMPIRAN

Tabel 10. Uji normalitas shapiro wilk analisis perbandingan kadar TNF- α antarkelompok.

| Kelompok | Uji Normalitas Shapiro Wilk | |
|----------|-----------------------------|------|
| K1 | K2 | 0,19 |
| | K3 | 0,48 |
| | K4 | 0,82 |
| | K5 | 0,56 |
| | K6 | 0,62 |
| | K7 | 0,49 |
| K2 | K1 | 0,31 |
| | K3 | 0,48 |
| | K4 | 0,82 |
| | K5 | 0,56 |
| | K6 | 0,62 |
| | K7 | 0,49 |
| K3 | K1 | 0,31 |
| | K2 | 0,19 |
| | K4 | 0,82 |
| | K5 | 0,56 |
| | K6 | 0,62 |
| | K7 | 0,49 |
| K4 | K1 | 0,31 |
| | K2 | 0,19 |
| | K3 | 0,48 |
| | K5 | 0,56 |
| | K6 | 0,62 |
| | K7 | 0,49 |
| K5 | K1 | 0,31 |
| | K2 | 0,19 |
| | K3 | 0,48 |
| | K4 | 0,82 |
| | K6 | 0,62 |
| | K7 | 0,49 |
| K6 | K1 | 0,31 |
| | K2 | 0,19 |
| | K3 | 0,48 |
| | K4 | 0,82 |
| | K5 | 0,56 |
| | K7 | 0,49 |
| K7 | K1 | 0,31 |
| | K2 | 0,19 |

| | | |
|--|-----------|------|
| | K3 | 0,48 |
| | K4 | 0,82 |
| | K5 | 0,56 |
| | K6 | 0,62 |

Tabel 11. Uji normalitas shapiro wilk analisis perbandingan kadar IL-10 antarkelompok.

| Kelompok | | Uji Normalitas Shapiro Wilk |
|----------|-----------|-----------------------------|
| K1 | K2 | 0,96 |
| | K3 | 0,30 |
| | K4 | 0,26 |
| | K5 | 0,90 |
| | K6 | 0,44 |
| | K7 | 0,29 |
| K2 | K1 | 0,85 |
| | K3 | 0,30 |
| | K4 | 0,26 |
| | K5 | 0,90 |
| | K6 | 0,44 |
| | K7 | 0,29 |
| K3 | K1 | 0,85 |
| | K2 | 0,96 |
| | K4 | 0,26 |
| | K5 | 0,90 |
| | K6 | 0,44 |
| | K7 | 0,29 |
| K4 | K1 | 0,85 |
| | K2 | 0,96 |
| | K3 | 0,30 |
| | K5 | 0,90 |
| | K6 | 0,44 |
| | K7 | 0,29 |
| K5 | K1 | 0,85 |
| | K2 | 0,96 |
| | K3 | 0,30 |
| | K4 | 0,26 |
| | K6 | 0,44 |
| | K7 | 0,29 |
| K6 | K1 | 0,85 |
| | K2 | 0,96 |
| | K3 | 0,30 |
| | K4 | 0,26 |
| | K5 | 0,90 |

| | | |
|----|-----------|------|
| | K7 | 0,29 |
| K7 | K1 | 0,85 |
| | K2 | 0,96 |
| | K3 | 0,30 |
| | K4 | 0,26 |
| | K5 | 0,90 |
| | K6 | 0,44 |

Tabel 12. Perbandingan rerata kadar TNF- α antarkelompok

| Kelompok | | Mean Difference | Sig. (Post Hoc) | Uji Homogenitas Greenhouse-Geisser | One-way ANOVA |
|----------|-----------|-----------------|-----------------|------------------------------------|---------------|
| K1 | K2 | 1,46 | 0,430 | 0,337 | <0,001 |
| | K3 | -0,78 | 1 | | |
| | K4 | 1,35 | 0,041 | | |
| | K5 | 1,20 | 0,985 | | |
| | K6 | -5,59 | 0,005 | | |
| | K7 | 1,95 | 0,021 | | |
| K2 | K1 | -1,46 | 0,430 | | |
| | K3 | -2,24 | 0,475 | | |
| | K4 | -0,10 | 1 | | |
| | K5 | -0,26 | 1 | | |
| | K6 | -7,05 | 0,000 | | |
| | K7 | 0,48 | 1 | | |
| K3 | K1 | 0,78 | 1 | | |
| | K2 | 2,24 | 0,475 | | |
| | K4 | 2,13 | 0,094 | | |
| | K5 | 1,98 | 0,077 | | |
| | K6 | -4,81 | 0,038 | | |
| | K7 | 2,73 | 0,021 | | |
| K4 | K1 | -1,35 | 0,041 | | |
| | K2 | 0,10 | 1 | | |
| | K3 | -2,13 | 0,094 | | |
| | K5 | -0,15 | 1 | | |
| | K6 | -6,95 | 0,001 | | |
| | K7 | 0,59 | 1 | | |
| K5 | K1 | -1,20 | 0,985 | | |
| | K2 | 0,26 | 1 | | |
| | K3 | -1,98 | 0,077 | | |
| | K4 | 0,15 | 1 | | |
| | K6 | -6,79 | 0,005 | | |

| | | | | | |
|----|----|--------------|--------------|--|--|
| | K7 | 0,75 | 1 | | |
| K6 | K1 | 5,59 | 0,005 | | |
| | K2 | 7,05 | 0,000 | | |
| | K3 | 4,81 | 0,038 | | |
| | K4 | 6,95 | 0,001 | | |
| | K5 | 6,79 | 0,005 | | |
| | K7 | 7,54 | 0,002 | | |
| K7 | K1 | -1,95 | 0,021 | | |
| | K2 | -0,48 | 1 | | |
| | K3 | -2,73 | 0,021 | | |
| | K4 | -0,59 | 1 | | |
| | K5 | -0,75 | 1 | | |
| | K6 | -7,54 | 0,002 | | |

Keterangan: K1=Preventif + Kuratif LGG; K2=Preventif + Kuratif LGG dan Levofloxacin; K3=Kuratif LGG; K4=Kuratif LGG dan Levofloxacin; K5=Kuratif Levofloxacin; K6=Placebo (Kontrol Positif); K7=Sehat (Kontrol Negatif).

Tabel 13. Perbandingan rerata kadar IL-10 antarkelompok

| Kelompok | | Mean Difference | Sig. (Post Hoc) | Uji Homogenitas Greenhouse-Geisser | One-way ANOVA |
|----------|----|-----------------|-----------------|------------------------------------|---------------|
| K1 | K2 | -4,21 | 0,001 | 0,385 | <0,001 |
| | K3 | 0,96 | 0,050 | | |
| | K4 | -2,61 | 0,072 | | |
| | K5 | -1,19 | 0,080 | | |
| | K6 | 5,58 | 0,000 | | |
| | K7 | 3,64 | 0,004 | | |
| K2 | K1 | 4,21 | 0,001 | | |
| | K3 | 5,17 | 0,002 | | |
| | K4 | 1,59 | 0,258 | | |
| | K5 | 3,01 | 0,003 | | |
| | K6 | 9,79 | 0,000 | | |
| | K7 | 7,85 | 0,000 | | |
| K3 | K1 | -0,96 | 0,050 | | |
| | K2 | -5,17 | 0,002 | | |
| | K4 | -3,58 | 0,058 | | |
| | K5 | -2,16 | 0,053 | | |
| | K6 | 4,62 | 0,001 | | |
| | K7 | 2,67 | 0,012 | | |
| K4 | K1 | 2,61 | 0,072 | | |
| | K2 | -1,59 | 0,258 | | |
| | K3 | 3,58 | 0,058 | | |

| | | | | | |
|----|-----------|--------------|--------------|--|--|
| | K5 | 1,41 | 0,400 | | |
| | K6 | 8,20 | 0,000 | | |
| | K7 | 6,26 | 0,007 | | |
| K5 | K1 | 1,19 | 0,080 | | |
| | K2 | -3,01 | 0,003 | | |
| | K3 | 2,16 | 0,053 | | |
| | K4 | -1,41 | 0,400 | | |
| | K6 | 6,78 | 0,000 | | |
| | K7 | 4,84 | 0,002 | | |
| K6 | K1 | -5,58 | 0,000 | | |
| | K2 | -9,79 | 0,000 | | |
| | K3 | -4,62 | 0,001 | | |
| | K4 | -8,20 | 0,000 | | |
| | K5 | -6,78 | 0,000 | | |
| | K7 | -1,94 | 0,091 | | |
| K7 | K1 | -3,64 | 0,004 | | |
| | K2 | -7,85 | 0,000 | | |
| | K3 | -2,67 | 0,012 | | |
| | K4 | -6,26 | 0,007 | | |
| | K5 | -4,84 | 0,002 | | |
| | K6 | 1,94 | 0,091 | | |

Keterangan: K1=Preventif + Kuratif LGG; K2=Preventif + Kuratif LGG dan Levofloxacin; K3=Kuratif LGG; K4=Kuratif LGG dan Levofloxacin; K5=Kuratif Levofloxacin; K6=Placebo (Kontrol Positif); K7=Sehat (Kontrol Negatif).

Tabel 14. Estimasi rata-rata kadar TNF- α pada setiap kelompok.

Estimates

Measure: LGG

| TNF-a | Mean | Std. Error | 95% Confidence Interval | |
|-------|-------|------------|-------------------------|-------------|
| | | | Lower Bound | Upper Bound |
| 1 | 8.426 | .266 | 7.689 | 9.164 |
| 2 | 6.965 | .328 | 6.054 | 7.877 |
| 3 | 9.207 | .311 | 8.345 | 10.070 |
| 4 | 7.071 | .185 | 6.558 | 7.583 |

| | | | | |
|---|--------|------|--------|--------|
| 5 | 7.226 | .243 | 6.551 | 7.901 |
| 6 | 14.022 | .353 | 13.043 | 15.002 |
| 7 | 6.476 | .221 | 5.864 | 7.089 |

Tabel 15. Estimasi rata-rata kadar IL-10 pada setiap kelompok.

Estimates

Measure: LGG

| IL-10 | Mean | Std. Error | 95% Confidence Interval | |
|-------|--------|------------|-------------------------|-------------|
| | | | Lower Bound | Upper Bound |
| 1 | 9.823 | .120 | 9.489 | 10.157 |
| 2 | 14.034 | .160 | 13.591 | 14.477 |
| 3 | 8.858 | .241 | 8.190 | 9.526 |
| 4 | 12.439 | .316 | 11.562 | 13.316 |
| 5 | 11.022 | .164 | 10.568 | 11.476 |
| 6 | 4.235 | .142 | 3.841 | 4.629 |
| 7 | 6.178 | .288 | 5.379 | 6.978 |